Having a good listener in one’s life may help slow cognitive decline: study
By
Alicia Lasek
Aug 18, 2021
Older adults who have regular interactions with active listeners are more likely to have cognitive functioning that contradicts evidence of dementia-related brain changes, a new study finds.
Early Alzheimer’s diagnosis may unintentionally hamper social engagement
By
Alicia Lasek
Nov 23, 2021
Clinicians should identify strategies to alleviate the social impacts of dementia diagnoses and encourage patients to mobilize informal support networks, researchers say.
CMS shares new coverage details for Alzheimer’s drug Leqembi
By
Alicia Lasek
Jun 26, 2023
On the eve of an FDA decision, CMS has released new information about the detailed patient data that clinicians must provide to ensure Medicare coverage when prescribing Leqembi.
Dementia-related speech difficulties found to reflect patients’ native language
By
Alicia Lasek
Jan 10, 2020
Italian- and English-speaking patients with the same form of dementia had different speech symptoms that affected diagnostic measurements.
BREAKING: First appropriate use guidance published for Alzheimer’s drug Aduhelm
By
Alicia Lasek
Jul 27, 2021
The first set of guidelines has been published for clinicians who wish to prescribe the new drug aducanumab (Aduhelm) and to properly monitor its administration. The recommendations fill the gaps between...
Primary care clinicians on front lines of early Alzheimer’s care in rural U.S., study reveals
By
Alicia Lasek
Aug 09, 2022
Primary care doctors and NPs, rather than specialists, are more likely to provide care for early-onset dementias in rural areas.
Dementia unlikely for those who get past these hurdles, study finds
By
Alicia Lasek
Nov 02, 2019
A brief cognitive screening combined with an olfactory test may rule out future dementia in people with mild cognitive impairment, say researchers.
Pfizer finds itself playing defense after shelving a promising Alzheimer’s treatment
By
Alicia Lasek
Jun 06, 2019
A large pharmaceutical company has come under fire, following reports that it failed to pursue a promising Alzheimer’s disease treatment.
Who uses the care planning code? Memory-care expert says the answer matters
By
Alicia Lasek
Nov 21, 2019
A memory-care expert is the latest advocate for greater use and expansion of Medicare’s largely untapped dementia care planning benefit.
FDA advisers to vote on first drug to treat Alzheimer’s
By
Alicia Lasek
Oct 28, 2020
Advisers will consider whether to recommend that the amyloid beta-removing drug aducanumab be approved. The FDA has not reviewed an application for a new Alzheimer’s treatment for at least 15 years.